Page 136 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $1.54
52wk Low $0.22 NRx Pharmaceuticals, Inc. NRXP $0.32
1201 Orange Street
Wilmington, DE 19801

(USD - in millions) www.nrxpharma.com
Market Cap 25.9
Enterprise 27.1
Basic Shares Out. 83.25 COMPANY OVERVIEW
Float 52.01
Institutional Holdings 5.07% Detailed Analysis:Channelchek.com
Short Interest 1.57
Avg. 90-Day Volume 1.41 NRX Pharmaceuticals Inc is a clinical-stage, small molecule
pharmaceutical company which develops novel therapeutics for the
treatment of central nervous system disorders and life-threatening
pulmonary diseases. It has announced the commercialization of
EPS Data ZYESAMI (Aviptadil), an application for COVID-related respiratory
failure. It is also developing NRX-100/101, the first sequential drug
2021 2022 2023 regimen for bipolar depression in patients with acute suicidal ideation
CQ1 N/A N/A (0.16) and behaviour.
CQ2 N/A (0.11) (0.12)

CQ3 N/A (0.14) (0.07)
CQ4 N/A (0.16) (0.12)
CY N/A (0.61) (0.51) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.07
ROE (ttm) -682.61
Debt-to-Total Cap. (mrq) 261.40
Fiscal Year End 31-Dec
1201 Orange SWilmington DE 19801

Key Executives
CEO: Willard, Stephen
CFO: Narido, Richard
COO: N/A
IR: Messere, Suzanne
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures